Ranibizumab to Treat Type 2 Idiopathic Macular Telangiectasia (RAMA-Trial)

Inclusion Criteria: * diagnosis of type 2 idiopathic macular telangiectasia * minimum of 18 years * patient must be able to follow protocol * written informed consent * best corrected visual acuity between 20/200 - 20/32 in the treated eye Exclusion Criteria: * patients who do not fulfill the inclusion criteria * patients with other retinal vascular disease such as diabetic retinopathy or venous occlusive diseases * ocular surgery 3 months before study enrollment * history of uncontrolled glaucoma * active intraocular inflammation or inflammation of the ocular adnexa * subfoveal fibrosis in the study eye * inability to follow study protocol * major surgery one month before study enrollment * history of severe cardiovascular disease or history of stroke 6 months before study enrollment * allergies against substances or components of the study medication * low anticipated compliance * patients who participate(d) in clinical trials simultaneously or within the last 60 days * pregnancy, lactation, women that may become pregnant and don't use safe contraception * chronic alcohol- or drug abuse within the last year * lacking legal competence or language ability * neurologic diseases such as multiple sclerosis * need of concomitant medication that is not allowed in combination with ranibizumab * previous intravitreal therapy with anti-angiogenic substances in the study eye within the last 6 months